EGFR and head and neck cancer: At last, CSM 3 was modified with a small protein anti-epidermal growth factor receptor (EGFR) affibody (CSM 3-affibody) for early-stage detection of head and neck cancers in which EGFR was overexpressed (Fig. 7O).